Company Filing History:
Years Active: 2023
Title: Aurelien Ginolhac: Innovator in Cancer Biomarkers
Introduction
Aurelien Ginolhac is a notable inventor based in Esch-sur-Alzette, Luxembourg. He has made significant contributions to the field of cancer research, particularly in the area of biomarkers for cancer diagnosis and prediction. His work aims to improve clinical outcomes for patients diagnosed with various types of cancer.
Latest Patents
Aurelien Ginolhac holds a patent for his invention titled "Biomarkers for cancer diagnosis, prediction or staging." This invention relates to a method for predicting clinical outcomes for subjects diagnosed with colorectal cancer, skin cancer, head and neck cancer, or lung cancer. Additionally, it provides a method for predicting whether a subject has a predisposition to develop such cancers, as well as aiding in the staging of these cancers. The methods utilize biomarkers such as MYO5B and/or RAB8A, and may also include RAB9A, RAB10, RAB11A, RAB25, CDC42, RAC, and/or RhoA.
Career Highlights
Aurelien Ginolhac is affiliated with the University of Luxembourg, where he continues to advance his research in cancer biomarkers. His innovative approach has the potential to significantly impact cancer diagnosis and treatment, providing valuable insights into patient care.
Collaborations
Aurelien collaborates with esteemed colleagues such as Elisabeth Letellier and Martine Schmitz, contributing to a dynamic research environment focused on cancer diagnostics.
Conclusion
Aurelien Ginolhac's work in cancer biomarkers exemplifies the importance of innovation in medical research. His contributions are paving the way for improved diagnostic methods and better patient outcomes in the fight against cancer.